Literature DB >> 9531375

Neoadjuvant chemotherapy followed by radiotherapy should not be a standard approach for locally advanced cervical cancer.

P W Shueng1, W L Hsu, Y M Jen, C J Wu, H S Liu.   

Abstract

PURPOSE: To investigate the role of neoadjuvant chemotherapy followed by radiotherapy in locally advanced cervical cancer. METHODS AND MATERIALS: This study cites all known literature on the subject in the English language. Articles were selected for analysis by MEDLINE and CANCERLINE computer searches. In Phase II trials, the response rates of some selective series were analyzed. However, This article will specially emphasize the result of all Phase III randomized trials.
RESULTS: Several investigators did obtain promising results from Phase II trials of neoadjuvant chemotherapy, mostly cisplatin-based combinations, followed by radiotherapy. However, most Phase III trials failed to demonstrate any benefit in terms of loco-regional relapse and/or survival by up-front chemotherapy.
CONCLUSION: The role of neoadjuvant chemotherapy remains to be defined, and the search for more active new agents must be continued. The neoadjuvant setting is still experimental and could not be recommended as a standard treatment at the present.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531375     DOI: 10.1016/s0360-3016(97)00906-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  [Simultaneous radiochemotherapy with cisplatin improves survival in cervical cancer].

Authors:  J Dunst; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

2.  [How toxic and effective is simultaneous radiochemotherapy with hydroxyurea, 5-FU and cisplatin in cervix carcinoma?].

Authors:  H Lindner
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

3.  Explanation for the failure of neoadjuvant chemotherapy to improve outcomes after radiotherapy for locally advanced uterine cervical cancer from the standpoint of the tumor regression rate.

Authors:  Kiyoshi Ohara; Hajime Tsunoda; Yumiko Oishi Tanaka; Kayoko Ohnishi; Keiko Nemoto; Takayuki Hashimoto; Nobuyoshi Fukumitsu; Masaharu Hata; Shinji Sugahara; Koichi Tokuuye; Hiroyuki Yoshikawa; Yasuyuki Akine
Journal:  Radiat Med       Date:  2007-02-27

4.  Timing of cisplatin administration for chemoradiotherapy in transgenic mice bearing lens tumors.

Authors:  Shoji Kaku; Norichika Ushioda; Hiroshi Ishii; Takashi Murakami; Kentaro Takahashi; Yuichiro Nakai; Koichiro Shimoya; Takafumi Nakamura
Journal:  Oncol Rep       Date:  2014-05-20       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.